Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
1.23M
-
Number of holders
-
9
-
Total 13F shares, excl. options
-
380K
-
Shares change
-
+9.78K
-
Total reported value, excl. options
-
$260K
-
Value change
-
+$6.37K
-
Number of buys
-
5
-
Number of sells
-
-3
-
Price
-
$0.69
Significant Holders of LIPELLA PHARMACEUTICALS INC. - Common Stock (LIPO) as of Q1 2024
10 filings reported holding LIPO - LIPELLA PHARMACEUTICALS INC. - Common Stock as of Q1 2024.
LIPELLA PHARMACEUTICALS INC. - Common Stock (LIPO) has 9 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 380K shares
of 1.23M outstanding shares and own 30.85% of the company stock.
Largest 10 shareholders include SABBY MANAGEMENT, LLC (250K shares), GEODE CAPITAL MANAGEMENT, LLC (42.1K shares), VANGUARD GROUP INC (34.5K shares), CITADEL ADVISORS LLC (22.1K shares), TWO SIGMA INVESTMENTS, LP (13.1K shares), HRT FINANCIAL LP (10.3K shares), Tower Research Capital LLC (TRC) (7.71K shares), FMR LLC (65 shares), WELLS FARGO & COMPANY/MN (30 shares), and UBS Group AG (0 shares).
This table shows the top 9 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.